Immunocore's Pipeline Expansion Was Supposed to Reduce KIMMTRAK Dependence But Has It

Immunocore Holdings (NASDAQ: IMCR) reports first-quarter 2026 earnings on May 6, 2026, with analysts expecting a loss of $0.26 per share. The commercial-stage biotechnology company faces a critical test as investors assess whether its lead product KIMMTRAK can sustain momentum after a volatile earnings track record, while the company advances multiple late-stage clinical trials that could define its future beyond the current melanoma franchise. With analyst sentiment deteriorating and technical indicators flashing warning signals, this report will reveal whether Immunocore can stabilize its commercial trajectory and validate its expanding pipeline investments.

Part 1: Earnings Preview

Immunocore Holdings is a commercial-stage biotechnology company pioneering immunomodulating medicines using its proprietary T cell receptor (TCR) technology platform, with its lead product KIMMTRAK approved in 39 countries for HLA-A*02:01 positive patients with unresectable or metastatic uveal melanoma. The company is advancing a diverse clinical pipeline beyond melanoma into other tumor types, infectious diseases including HIV, and autoimmune conditions.

For the first quarter of 2026, analysts expect Immunocore to report a loss of $0.26 per share when it announces results on May 6. The company most recently reported fourth-quarter 2025 results with an actual loss of $0.60 per share. Compared to the same quarter last year (Q1 2025), when the company reported earnings of $0.10 per share, the current estimate represents a dramatic reversal—a -360% decline—signaling heightened investor concern about the company's profitability trajectory.

Three key themes define this earnings story:

KIMMTRAK Revenue Trajectory and Growth Moderation: After delivering $400 million in full-year 2025 sales with 15 consecutive quarters of growth, management has guided investors to expect "moderating revenue growth in 2026." Fourth-quarter sales of $104.5 million represented 24% year-over-year growth, but the deceleration from earlier quarters raises questions about market saturation in metastatic uveal melanoma and the pace of community penetration in the United States, where mean duration of treatment has increased to 14 months. Investors will scrutinize Q1 revenue trends and updated guidance to assess whether KIMMTRAK has reached an inflection point in its commercial lifecycle.

Late-Stage Clinical Trial Execution and Data Catalysts: The company is preparing for potentially transformative data readouts in 2026, with enrollment completion anticipated in the first half for the TEBE-AM trial (second-line cutaneous melanoma) and topline overall survival data expected as early as the second half. Management also plans to present Phase 1/2 data from the PRAME franchise (brenetafusp in ovarian and lung cancer, plus the half-life extended candidate IMC-P115C) in the second half of 2026. The ability to deliver on these clinical milestones while managing R&D expenses—which surged to $274.9 million in 2025 from $222.2 million in 2024—will be critical to maintaining investor confidence in the pipeline's value proposition.

Profitability Path and Cash Burn: Despite achieving $400 million in annual revenue, Immunocore posted a full-year 2025 net loss of $35.5 million, an improvement from the $51.1 million loss in 2024 but still reflecting significant cash consumption. With $864.2 million in cash and marketable securities as of December 31, 2025, the company has financial flexibility, but investors will focus on the trajectory toward profitability and whether the expanding pipeline investments—including the first autoimmune trial initiation planned for the first half of 2026—can be balanced against the need to demonstrate sustainable economics in the core KIMMTRAK business.

Analyst commentary ahead of the release reflects cautious optimism tempered by execution concerns. HC Wainwright maintained its Buy rating with a $100 price target, emphasizing the company's "diverse clinical portfolio" and the potential for TEBE-AM data to unlock significant value in the larger cutaneous melanoma market. However, the recent deterioration in analyst sentiment—with one analyst downgrading to Strong Sell in the past month—suggests growing skepticism about near-term profitability and the risk that clinical trial delays or disappointing data could undermine the investment thesis. Analysts are particularly focused on management's commentary regarding the pace of KIMMTRAK adoption in the community setting and any updated timelines for the three Phase 3 trials (TEBE-AM, ATOM, and PRISM-MEL-301) that represent the company's most significant near-term value drivers.

Part 2: Historical Earnings Performance

Immunocore has demonstrated an inconsistent earnings track record over the past four quarters, with results swinging dramatically between beats and misses. In Q1 2025 (March 2025), the company delivered a significant positive surprise, reporting earnings of $0.10 per share against expectations of -$0.35, a +128.57% beat. This was followed by a modest beat in Q2 2025 (June 2025), where the company reported -$0.20 versus estimates of -$0.21 (+4.76% beat). The volatility continued in Q3 2025 (September 2025) with another substantial beat, reporting $0.00 against expectations of -$0.30 (+100.00% beat).

However, the most recent quarter (Q4 2025, December 2025) marked a sharp reversal, with the company reporting a loss of -$0.60 per share against estimates of -$0.28, representing a -114.29% miss—the largest earnings disappointment in the recent history. This miss is particularly concerning given the pattern of beats in the three preceding quarters, suggesting potential challenges in the business that caught both management and analysts off guard.

The pattern reveals no consistent trend in earnings performance—the company has alternated between significant beats and a major miss, making it difficult for investors to predict outcomes with confidence. The dramatic swing from a $0.00 result in Q3 to a -$0.60 loss in Q4 raises questions about earnings visibility and whether the company's profitability trajectory is as stable as the revenue growth might suggest. Heading into Q1 2026, investors will be watching closely to see whether the company can return to the positive surprise pattern of earlier 2025 quarters or if the Q4 miss signals a more fundamental deterioration in the business economics.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Immunocore typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.

Immunocore's stock has exhibited moderate to high volatility around earnings announcements, with an average absolute Day 0 move of 3.12% and an average Day 0 range of 7.63%. The Day +1 follow-through shows an average absolute move of 1.64% with a range of 5.14%, indicating that the initial post-earnings reaction tends to be larger than the subsequent session's movement.

The most recent earnings release (February 25, 2026) produced the largest Day 0 decline in the dataset, with the stock falling -4.51% and trading in a 9.09% range—significantly above the historical average. This sharp negative reaction coincided with the company's Q4 2025 earnings miss. In contrast, the May 2025 report (which delivered a strong earnings beat) generated a +6.63% Day 0 gain, the largest positive move in the recent history.

The data reveals a directional bias toward positive Day 0 moves in most quarters, with five of the seven reported periods showing gains on the day of the announcement. However, the Day +1 follow-through has been more mixed, with several instances of reversal—notably after the February 2025 report, which saw a +5.34% Day 0 gain followed by a -3.87% Day +1 decline. This pattern suggests that while the market often reacts positively to initial headlines, deeper analysis of the results and management commentary can lead to profit-taking or reassessment in the following session.

Investors should anticipate meaningful price movement around the May 6 earnings release, with historical patterns suggesting a potential swing of 7-10% in the Day 0 range and continued volatility into the following session. The recent Q4 miss and subsequent negative price action may have reset expectations, but the stock's tendency toward sharp moves in both directions means positioning ahead of the report carries significant risk.

Part 2.2: Options Market Expected Move

The options market is pricing in an expected move of 0.00% for the May 15 expiration, which is significantly below the stock's average historical Day 0 move of 3.12% and Day 0 range of 7.63% around earnings. This disconnect suggests either extremely low options activity (total open interest of just 47 contracts) or a data anomaly, as the historical earnings volatility would typically command a much higher implied move. Investors should note that the average volatility of 98.49% indicates substantial uncertainty in the options market, even if the specific expected move calculation appears understated.

Part 3: What Analysts Are Saying

Analysts maintain a bullish stance on Immunocore, with the consensus rating at 4.19 out of 5.0 (between Buy and Strong Buy), though sentiment has deteriorated over the past month from 4.31. The average price target of $63.85 implies 121% upside from the current price of $28.84, with estimates ranging from a low of $33.00 to a high of $100.00—a wide spread that reflects divergent views on the company's pipeline value and commercial trajectory.

The current analyst breakdown shows 10 Strong Buys, 1 Moderate Buy, 4 Holds, and 1 Strong Sell among the 16 analysts covering the stock. Notably, the composition has shifted in the past month, with one analyst moving from Hold to Strong Sell—the first Strong Sell rating in the recent period—while one Hold rating was upgraded. This mixed movement, combined with the decline in the average recommendation score, signals growing skepticism among some analysts about the company's near-term prospects, likely reflecting concerns about the Q4 earnings miss, moderating revenue growth guidance, and the uncertain timeline for pipeline catalysts.

The 121% implied upside to the consensus target is substantial, suggesting that analysts who remain bullish see significant value in the company's late-stage clinical programs, particularly the potential for TEBE-AM data in second-line cutaneous melanoma and the PRISM-MEL-301 trial in first-line melanoma. However, the emergence of a Strong Sell rating and the wide target range ($33.00 to $100.00) indicate that this upside case is far from consensus, with bears questioning whether the company can execute on its clinical milestones while managing profitability and whether the current valuation adequately reflects execution risk. The deteriorating sentiment trend heading into earnings suggests that analysts are adopting a more cautious posture, likely waiting for clearer evidence of sustained commercial momentum and clinical progress before reaffirming their bullish views.

Part 4: Technical Picture

The Barchart Technical Opinion for Immunocore is decisively bearish heading into earnings, with a 100% Sell signal that has strengthened from 72% Sell a month ago and 100% Sell a week ago. This consistent and intensifying negative signal reflects deteriorating technical momentum across all timeframes.

Timeframe Analysis:

• Short-term (100% Sell): Strong sell signal indicates immediate downward pressure and negative near-term momentum
• Medium-term (100% Sell): Persistent sell signal suggests the intermediate-term trend has firmly turned negative with no signs of stabilization
• Long-term (100% Sell): Bearish long-term signal reflects sustained weakness in the broader trend structure

Trend Characteristics: The signal strength is classified as Strong and is Strengthening, indicating that the bearish technical environment is not only firmly established but intensifying as the stock approaches its earnings release.

The stock is currently trading at $28.84, positioned above its 5-day moving average of $28.27 and above its 10-day moving average of $28.72, providing minimal short-term support. However, the stock has broken below all longer-term moving averages: the 20-day ($30.03), 50-day ($30.84), 100-day ($32.37), and 200-day ($33.42). This configuration—where the stock trades below all major intermediate and long-term moving averages—is a classic bearish setup that suggests the path of least resistance remains to the downside.

The technical picture is decidedly cautionary heading into the May 6 earnings release. With the stock trading below all key moving averages beyond the 10-day and the Barchart Technical Opinion showing maximum bearish intensity across all timeframes, the setup suggests limited technical support if the earnings report disappoints. The 20-day moving average at $30.03 represents the nearest resistance level, while a break below the 10-day average at $28.72 could accelerate downside momentum. The strengthening sell signal and deteriorating trend structure indicate that any positive earnings surprise would need to be substantial to overcome the negative technical backdrop and trigger a sustained reversal. Investors should be prepared for heightened volatility, with the technical environment offering little cushion against further downside if results or guidance fall short of expectations.